Reducing the costs of blockbuster gene and cell therapies in the Global South

Researchers in low- and middle-income countries are developing their own IP, scaling up local manufacturing, and looking for biomarkers — all in the hope of bringing costs down and getting therapies to people who need them.

We are living in the age of biology, where new research is translated daily into potential treatments for deadly diseases. Researchers are conducting thousands of clinical trials to assess the efficacy of these first-in-human therapeutics, but alongside excitement, innovation brings costs. These costs are paid by healthcare providers and patients, leaving many blockbuster treatments, from gene therapy and chimeric antigen receptor (CAR)-T cells to immune checkpoint inhibitors, out of reach for most of the world.

This is a preview of subscription content, access via your institution

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

209,00 € per year

only 17,42 € per issue

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Log in

Learn about institutional subscriptions

Read our FAQs

Contact customer support

Author information

Authors and Affiliations

London, UK

Ben Johnson

About this article

Cite this article

Johnson, B. Reducing the costs of blockbuster gene and cell therapies in the Global South.
Nat Biotechnol (2024). https://doi.org/10.1038/s41587-023-02049-3

Download citation

Published: 11 January 2024

DOI: https://doi.org/10.1038/s41587-023-02049-3

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Nature.com – https://www.nature.com/articles/s41587-023-02049-3